litlas
Log inCreate account

Richard Pazdur

Active 1987–2025

321
Papers
55,756
Citations
134
h-index
312
i10-index

Citations

Citations per year for Richard Pazdur1948: 3 citations1987: 1 citations1989: 4 citations1990: 4 citations1991: 8 citations1992: 9 citations1993: 7 citations1994: 20 citations1995: 18 citations1996: 25 citations1997: 14 citations1998: 21 citations1999: 31 citations2000: 31 citations2001: 57 citations2002: 66 citations2003: 84 citations2004: 138 citations2005: 185 citations2006: 175 citations2007: 169 citations2008: 219 citations2009: 263 citations2010: 266 citations2011: 238 citations2012: 237 citations2013: 227 citations2014: 300 citations2015: 320 citations2016: 328 citations2017: 404 citations2018: 472 citations2019: 1,753 citations2020: 2,279 citations2021: 2,416 citations2022: 2,162 citations2023: 1,752 citations2024: 2,830 citations2025: 1,413 citations2026: 52 citations1949–1986: no citations, so these years are not shown1988: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 6,884 citing papers, 27% of this breakdownChina: 3,048 citing papers, 11.9% of this breakdownItaly: 1,504 citing papers, 5.9% of this breakdownUnited Kingdom: 1,312 citing papers, 5.1% of this breakdownGermany: 1,304 citing papers, 5.1% of this breakdownFrance: 1,004 citing papers, 3.9% of this breakdownSpain: 819 citing papers, 3.2% of this breakdownCanada: 801 citing papers, 3.1% of this breakdownJapan: 686 citing papers, 2.7% of this breakdownNetherlands: 617 citing papers, 2.4% of this breakdownIndia: 607 citing papers, 2.4% of this breakdownAustralia: 578 citing papers, 2.3% of this breakdown
0%27%Other 25%

Institutions

Fields

  • Medicine65.2%
  • Biochemistry, Genetics and Molecular Biology23.5%
  • Immunology and Microbiology2.8%
  • Materials Science1.7%
  • Computer Science1.1%
  • Engineering1.1%
  • Other4.6%

Topics

  • Cancer Immunotherapy and Biomarkers5.7%
  • CAR-T cell therapy research3%
  • Lung Cancer Treatments and Mutations3%
  • HER2/EGFR in Cancer Research3%
  • Breast Cancer Treatment Studies2.7%
  • Cancer Genomics and Diagnostics2.2%
  • Other80.4%

Coauthors

All papers

Open in search
  1. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Authors: Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P. Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M. Swain, Tatiana M. Prowell, Sibylle Loibl, D. Lawrence Wickerham, Jan Bogaerts, José Baselga, Charles M. Perou, Gideon M. Blumenthal, Jens‐Uwe Blohmer, Eleftherios P. Mamounas, Jonas Bergh, Semiglazov Vf, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A. Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E. Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, W. Eiermann, Gϋnter von Minckwitz - The Lancet 2014 cited by 4,710

  2. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

    Authors: Leigh Marcus, Lola A. Fashoyin‐Aje, Martha Donoghue, Mengdie Yuan, Lisa Rodríguez, Pamela Gallagher, Reena Philip, Soma Ghosh, Marc R. Theoret, Julia A. Beaver, Richard Pazdur, Steven J. Lemery - Clinical Cancer Research 2021 cited by 568

  3. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors

    Authors: Leigh Marcus, Steven J. Lemery, Patricia Keegan, Richard Pazdur - Clinical Cancer Research 2019 cited by 1,154

  4. Trends in the approval of cancer therapies by the FDA in the twenty-first century

    Authors: Emma Scott, Andrea Baines, Yutao Gong, Rodney Moore, Gülsüm Emel Pamuk, Haleh Saber, Ashim Subedee, Matthew D. Thompson, Wenming Xiao, Richard Pazdur, V. Ashutosh Rao, Julie A. Schneider, Julia A. Beaver - Nature Reviews Drug Discovery 2023 cited by 269

  5. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

    Authors: Robert Q. Le, Liang Li, Weishi Yuan, Stacy S. Shord, Lei Nie, Bahru Habtemariam, Donna Przepiorka, Ann T. Farrell, Richard Pazdur - The Oncologist 2018 cited by 882

  6. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

    Authors: Jaleh Fallah, Sundeep Agrawal, Haley Gittleman, Mallorie H. Fiero, Sriram Subramaniam, Christy S. John, Wei Chen, Tiffany K. Ricks, Gang Niu, Anthony F. Fotenos, Min Wang, Kelly Chiang, William F. Pierce, Daniel L. Suzman, Shenghui Tang, Richard Pazdur, Laleh Amiri‐Kordestani, Amna Ibrahim, Paul G. Kluetz - Clinical Cancer Research 2022 cited by 220

  7. FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC

    Authors: Erica C. Nakajima, Nicole Drezner, Xiaoxue Li, Pallavi S. Mishra‐Kalyani, Yajun Liu, Hong Zhao, Youwei Bi, Jiang Liu, Atiqur Rahman, Emily Wearne, Idara Ojofeitimi, Lauren Tesh Hotaki, Dianne Spillman, Richard Pazdur, Julia A. Beaver, Harpreet Singh - Clinical Cancer Research 2021 cited by 305

  8. FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma

    Authors: Bhupinder Mann, John R. Johnson, Martin H. Cohen, Robert Justice, Richard Pazdur - The Oncologist 2007 cited by 1,353

  9. FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

    Authors: Maura O’Leary, Xiaobin Lü, Ying Huang, Xue Lin, Iftekhar Mahmood, Donna Przepiorka, Denise Gavin, Shiowjen Lee, Ke Liu, Bindu George, Wilson W. Bryan, Marc R. Theoret, Richard Pazdur - Clinical Cancer Research 2018 cited by 291

  10. The Drug-Dosing Conundrum in Oncology — When Less Is More

    Authors: Mirat Shah, Atiqur Rahman, Marc R. Theoret, Richard Pazdur - New England Journal of Medicine 2021 cited by 278

  11. FDA Approval: Blinatumomab

    Authors: Donna Przepiorka, Chia‐Wen Ko, Albert Deisseroth, Carolyn L. Yancey, Reyes Candau-Chacon, Haw-Jyh Chiu, Brenda J. Gehrke, Candace Gomez-Broughton, Robert C. Kane, Susan Kirshner, Nitin Mehrotra, Tiffany K. Ricks, Deborah H. Schmiel, Pengfei Song, Ping Zhao, Qing Zhou, Ann T. Farrell, Richard Pazdur - Clinical Cancer Research 2015 cited by 364

  12. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

    Authors: Kelly J. Norsworthy, Chia‐Wen Ko, Jee Eun Lee, Jiang Liu, Christy S. John, Donna Przepiorka, Ann T. Farrell, Richard Pazdur - The Oncologist 2018 cited by 259

  13. FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

    Authors: Sakar Wahby, Lola A. Fashoyin‐Aje, Christy Osgood, Joyce Cheng, Mallorie H. Fiero, Lijun Zhang, Shenghui Tang, Salaheldin S. Hamed, Pengfei Song, Rosane Charlab, Sarah E. Dorff, Tiffany K. Ricks, Kimberly Barnett-Ringgold, Jeannette Dinin, Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, Laleh Amiri‐Kordestani, Julia A. Beaver - Clinical Cancer Research 2020 cited by 150

  14. Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients

    Authors: Jeanne Fourie Zirkelbach, Mirat Shah, Jonathon Vallejo, Joyce Cheng, Amal Ayyoub, Jiang Liu, Rachel Hudson, Rajeshwari Sridhara, Gwynn Ison, Laleh Amiri‐Kordestani, Shenghui Tang, Thomas Gwise, Atiqur Rahman, Richard Pazdur, Marc R. Theoret - Journal of Clinical Oncology 2022 cited by 165

  15. FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer

    Authors: Preeti Narayan, Christy Osgood, Harpreet Singh, Haw-Jyh Chiu, Tiffany K. Ricks, Edwin C.Y. Chow, Junshan Qiu, Pengfei Song, Jingyu Yu, Frances Namuswe, Maria Guiterrez-Lugo, Sherry Hou, William F. Pierce, Kirsten B. Goldberg, Shenghui Tang, Laleh Amiri‐Kordestani, Marc R. Theoret, Richard Pazdur, Julia A. Beaver - Clinical Cancer Research 2021 cited by 164

  16. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer

    Authors: Shaily Arora, Sanjeeve Balasubramaniam, Hui Zhang, Tara Berman, Preeti Narayan, Daniel L. Suzman, Erik Bloomquist, Shenghui Tang, Yutao Gong, Rajeshwari Sridhara, Francisca Reyes Turcu, Deb Chatterjee, Banu Saritas-Yildirim, Soma Ghosh, Reena Philip, Anand Pathak, Jennifer Gao, Laleh Amiri‐Kordestani, Richard Pazdur, Julia A. Beaver - The Oncologist 2020 cited by 182

  17. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer

    Authors: Julia A. Beaver, Laleh Amiri‐Kordestani, Rosane Charlab, Wei Chen, Todd R. Palmby, Amy Tilley, Jeanne Fourie Zirkelbach, Jingyu Yu, Qi Liu, Liang Zhao, Joyce Z. Crich, Xiao Hong Chen, Minerva Hughes, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Paul G. Kluetz, Geoffrey Kim, Amna Ibrahim, Richard Pazdur, Patricia Cortazar - Clinical Cancer Research 2015 cited by 372

  18. Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

    Authors: V. Ellen Maher, Laura L. Fernandes, Chana Weinstock, Shenghui Tang, Sundeep Agarwal, Michael H. Brave, Yang‐Min Ning, Harpreet Singh, Daniel L. Suzman, James Xu, Kirsten B. Goldberg, Rajeshwari Sridhara, Amna Ibrahim, Marc R. Theoret, Julia A. Beaver, Richard Pazdur - Journal of Clinical Oncology 2019 cited by 346

  19. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors

    Authors: Jaleh Fallah, Michael H. Brave, Chana Weinstock, Gautam U. Mehta, Diana Bradford, Haley Gittleman, Erik Bloomquist, Rosane Charlab, Salaheldin S. Hamed, Claudia P. Miller, Sarah E. Dorff, Wiley Chambers, Bronwyn D. Mixter, Jeannette Dinin, William F. Pierce, Tiffany K. Ricks, Shenghui Tang, Martha Donoghue, Richard Pazdur, Laleh Amiri‐Kordestani, Amna Ibrahim, Julia A. Beaver - Clinical Cancer Research 2022 cited by 171

  20. FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer

    Authors: Asma Dilawari, Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H. Fiero, Ankit Shah, Salaheldin S. Hamed, Junshan Qiu, Jingyu Yu, Wimolnut Manheng, Tiffany K. Ricks, Rajan Pragani, Arulvathani Arudchandran, Paresma Patel, Shadia Zaman, Arpita Roy, Shyam Kalavar, Soma Ghosh, William F. Pierce, Nam Atiqur Rahman, Shenghui Tang, Bronwyn D. Mixter, Paul G. Kluetz, Richard Pazdur, Laleh Amiri‐Kordestani - Clinical Cancer Research 2023 cited by 105

  21. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

    Authors: Geoffrey Kim, Gwynn Ison, Amy E. McKee, Hui Zhang, Shenghui Tang, Thomas Gwise, Rajeshwari Sridhara, Eunice Lee, Abraham Tzou, Reena Philip, Haw-Jyh Chiu, Tiffany K. Ricks, Todd R. Palmby, Anne‐Marie Russell, Gaétan Ladouceur, Elimika Pfuma, Hongshan Li, Liang Zhao, Qi Liu, Rajesh Venugopal, Amna Ibrahim, Richard Pazdur - Clinical Cancer Research 2015 cited by 527

  22. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

    Authors: Elaine Chang, Chana Weinstock, Lijun Zhang, Rosane Charlab, Sarah E. Dorff, Yutao Gong, Vicky Hsu, Fang Li, Tiffany K. Ricks, Pengfei Song, Shenghui Tang, Peter Waldron, Jingyu Yu, Eias Zahalka, Kirsten B. Goldberg, Richard Pazdur, Marc R. Theoret, Amna Ibrahim, Julia A. Beaver - Clinical Cancer Research 2020 cited by 183

  23. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

    Authors: Jennifer Gao, Joyce Cheng, Erik Bloomquist, Jacquelyn Sanchez, Suparna Wedam, Harpreet Singh, Laleh Amiri‐Kordestani, Amna Ibrahim, Rajeshwari Sridhara, Kirsten B. Goldberg, Marc R. Theoret, Paul G. Kluetz, Gideon M. Blumenthal, Richard Pazdur, Julia A. Beaver, Tatiana M. Prowell - The Lancet Oncology 2019 cited by 297

  24. FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

    Authors: Laleh Amiri‐Kordestani, Gideon M. Blumenthal, Qiang Xu, Lijun Zhang, Shenghui Tang, Linan Ha, Wendy C. Weinberg, Bo Chi, Reyes Candau-Chacon, P. E. Hughes, Anne‐Marie Russell, Sarah Pope Miksinski, Xiao Hong Chen, W. David McGuinn, Todd R. Palmby, Sarah J. Schrieber, Qi Liu, Jian Wang, Pengfei Song, Nitin Mehrotra, Lisa Skarupa, Kathleen A. Clouse, Ali Al‐Hakim, Rajeshwari Sridhara, Amna Ibrahim, Robert Justice, Richard Pazdur, Patricia Cortazar - Clinical Cancer Research 2014 cited by 345